The Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) funding call from the National Institute of Mental Health (NIMH) supports early stage testing of pharmacologic interventions with novel mechanisms of action or neuromodulatory device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Applications are open to researchers at research institutions in the USA and worldwide, including small businesses and other for-profit organizations.
The grant provides funding for 5 years (plus indirect costs).
Funding opportunity number: PAR-25-184
Applications close on June 15, 2026.